bioAffinity Technologies ... (BIAF)
0.49
-0.01 (-1.76%)
At close: Apr 16, 2025, 12:29 PM
Company Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics.
The company offers CyPath lung, a diagnostic test, for early detection of lung cancer.
It also researches targeted therapies to treat cancer at the cellular level.
The company was founded in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies Inc.
| Country | United States |
| IPO Date | Sep 1, 2022 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Maria Zannes J.D. |
Contact Details
Address: 22211 West Interstate 10 San Antonio, Texas United States | |
| Website | https://www.bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W109 |
| ISIN Number | US09076W1099 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer & Director |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dallas J. Coleman | Vice President of sales |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Julie Anne Overton | Director of Communications |
| Steven Girgenti | Founder & Executive Chairman of the Board |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | PRE 14A | Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 11, 2025 | S-1 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 424B5 | Filing |
| Feb 25, 2025 | 424B5 | Filing |
| Feb 07, 2025 | 8-K | Current Report |